EN DE
STOCK COMPARISON

Alibaba Health Information Technology vs BioScience Health Innovations: Fair Value & Quality

Both stocks run through our valuation models. Here is how Alibaba Health Information Technology (0241) and BioScience Health Innovations (BHIC) compare, as of Sep 28, 2026.

As of Sep 28, 2026, Fair Value Calculator sees Alibaba Health Information Technology as the less overvalued of the two: Alibaba Health Information Technology trades at HK$2.83 versus a fair value of HK$2.34 (−17.2%), while BioScience Health Innovations trades at $7.11 versus $0.86 (−87.9%).
Alibaba Health Information Technology
0241.HK · HKD · Health Care
−17.2%
upside to fair value
overvalued
PriceHK$2.83
Fair ValueHK$2.34
Quality64/100
BioScience Health Innovations
BHIC · USD · Health Care
−87.9%
upside to fair value
overvalued
Price$7.11
Fair Value$0.86
Quality60/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Alibaba Health Information TechnologyBioScience Health Innovations
Valuation
20.2×P/E (TTM)139.3×
17.5×Forward P/E (FY2028)n/a
1.34×P/S (TTM)18.07×
2.57×P/Bn/a
21.5×EV/EBITDAn/a
0.69×PEGn/a
−17.2%Fair value upside−87.9%
2.1%Dividend yieldn/a
HK$0.06Dividend per sharen/a
Profitability
4.1%Operating margin-21.0%
11.3%Return on equity-37.0%
5.2%Return on assets-18.3%
Growth
7.6%Revenue growth (YoY)-41.0%
8.6%Avg. growth/yr (3Y)334.5%
17.2%Avg. growth/yr (5Y)n/a
+39.0%Value creation/yrn/a
Balance & size
1,357.4×Interest coverage (EBIT/interest)n/a
$6BMarket cap$81M
healthyGrowth qualityexpensive
Forward P/E: price divided by the analyst consensus for the first fiscal year that has not started yet. The current year carries special items from quarters already reported.

Alibaba Health Information Technology leads: 6 to 1 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Alibaba Health Information Technologyof which business quality 64 · market factors 14 BioScience Health Innovationsof which business quality 66 · market factors 66
ProfitabilityMargins and returns on capital today
60
90
Quality GrowthAre margins and returns improving?
56
75
CashflowEarnings quality: real cash, not paper profit
41
25
Fin. StrengthBalance sheet, leverage, solvency risk
97
100
InvestmentDisciplined investing over empire-building
85
50
Low VolatilityCalm price path (market factor)
27
27
MomentumPrice trend over the last 3–12 months (market factor)
13
80
52W MomentumDistance to the 52-week high (market factor)
0
86
Net IssuanceShare count: buybacks or dilution?
47
42

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAlibaba Health Information TechnologyPrice HK$2.83BioScience Health InnovationsPrice $7.11
DCF Models0%close to the priceHK$2.82−87.6%below the price$0.88
Earnings-Based+48.3%above the priceHK$4.19−73.1%below the price$1.91
Dividend Discount−77.0%below the priceHK$0.65n/a
Multiples−28.5%below the priceHK$2.02−86.9%below the price$0.93
Asset-Based−73.8%below the priceHK$0.74−98.9%below the price$0.08
Growth DCF−12.4%close to the priceHK$2.48−91.4%below the price$0.62
Economic Profit−58.6%below the priceHK$1.17−92.8%below the price$0.51
Growth Earnings+96.8%above the priceHK$5.56−64.3%below the price$2.54
Minimum−77.0%below the priceHK$0.65−98.9%below the price$0.08
Maximum+96.8%above the priceHK$5.56−64.3%below the price$2.54
Median−20.4%below the priceHK$2.25−87.6%below the price$0.88
Geometric mean−32.0%below the priceHK$1.92−89.9%below the price$0.72

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Alibaba Health Information Technology: 18 of 26 models see the stock below the current price.

BioScience Health Innovations: 20 of 20 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Alibaba Health Information Technology
Price HK$2.83
Fair Value HK$2.34
Bear HK$1.46Bull HK$3.24
BioScience Health Innovations
Price $7.11
Fair Value $0.86
Bear $0.44Bull $1.16

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Alibaba Health Information Technology · Health Care

Quality score64 · Top 25%
Fair value upside−17.2% · above median

BioScience Health Innovations · Health Care

Quality score60 · above median
Fair value upside−87.9% · bottom 25%

Bottom line

As of Sep 28, 2026, Fair Value Calculator sees Alibaba Health Information Technology as the less overvalued of the two: Alibaba Health Information Technology trades at HK$2.83 versus a fair value of HK$2.34 (−17.2%), while BioScience Health Innovations trades at $7.11 versus $0.86 (−87.9%).

Alibaba Health Information Technology has the higher quality score (64/100).

Open Alibaba Health Information Technology live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.